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A cardinal feature of the syndrome of heart failure, irrespec-
tive of ejection fraction, is exercise intolerance, which is
strongly associated with quality of life and clinical outcomes
(1). Methods to evaluate exercise tolerance include self-
reports of activities of daily living, clinician assessment of
New York Heart Association functional class, and provoc-
ative stress testing. Cardiopulmonary exercise testing has
emerged as an objective and reproducible means of quanti-
fying oxygen consumption (1), which is determined by
multiple factors including lung function, cardiac output,
hemoglobin, and peripheral factors that include the ability
to vasodilate, ensuring adequate delivery of oxygenated
blood to exercising muscles and the ability of these muscles
to utilize oxygen during exercise (2).
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In this issue of the Journal, Haykowsky et al. (3) have
further advanced our understanding of exercise intolerance
in subjects with heart failure and a preserved ejection faction
(HFPEF) by analyzing data from a small randomized
clinical trial of cardiac rehabilitation. Such work is essential
in that this form of heart failure now accounts for a majority
of the incident cases, is poorly understood physiologically,
and hence has no specific therapies that have been demon-
strated to prolong life in this cohort (4). The investigators
performed simultaneous measurement of oxygen consump-
tion and measures of cardiac output using 2-dimensional
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compensated subjects with HFPEF who were randomly
assigned to undergoing exercise training. Such data have
been employed to further our understanding of this complex
clinical syndrome (5), which has led us to fundamentally
question our understanding of the pathophysiology of this
disorder (6). In this secondary analysis of a previously
conducted small randomized clinical trial of cardiac reha-
bilitation that was shown to have clinical benefit for subjects
with HFPEF, the investigators demonstrate that the mech-
anisms underlying the improvement in peak oxygen con-
sumption (VO2) in this population have a “peripheral” and
not a “central hemodynamic” basis.
Mechanisms underlying exercise intolerance in heart
failure have been primarily studied in patients with systolic
heart failure and reduced ejection fraction (7–10). Early
work showed a lack of correlation between impaired left
ventricular function and exercise performance (11) and
resulted in the analysis of peripheral factors contributing to
impaired exercise performance on heart failure. Subsequent
studies demonstrated a central role of skeletal muscle
dysfunction and abnormal metabolism defining impaired
exercise function in patients with heart failure. Ultrastruc-
tural analyses revealed a distinct quantitative shift in muscle
fiber types from oxidative slow-twitch type I fibers to more
glycolytic fast-twitch type II muscle fibers (8). This is
accompanied by abnormal mitochondrial function and struc-
ture (8), sarcolemmal abnormalities with impaired skeletal
muscle calcium homeostasis with decreased SERCA 1a
levels (12), reduced phosphocreatine and glycogen content
(9), increased oxidative stress (13), and endothelial dysfunc-
tion accompanied by reduced capillary density (14). Im-
paired skeletal muscle anabolic metabolism is characterized
by decreased muscle bulk and fiber cross-sectional area
(2,15), reduced local insulin-like growth factor-1 expression
(15), and systemic growth hormone resistance (16). Local
inflammation in skeletal muscle with increased levels of
interleukin-1 and tumor necrosis factor- as well as
inducible nitric oxide synthase (17) might further contribute
to the progressive deterioration of skeletal muscle structure,
function, and metabolism.
Geriatricians have for decades recognized a progressive
decline in muscle mass, strength, and function that occurs
with normal human aging, termed sarcopenia, which is
worsened by concomitant disorders such as heart failure
(18). Sarcopenia is associated with poor endurance, physical
inactivity, slow gait speed, and decreased mobility, all
features of the frailty syndrome (19) and heart failure with
a preserved ejection fraction (20). Similar to the aforemen-
tioned changes in muscle structure and function observed in
the phenotype of systolic heart failure, sarcopenia has been
associated with oxidative protein damage, cytokines, and
insulin-like growth factor-1 (21). The geriatric cardiology
community is beginning to embrace these findings with an
emerging focus on functional capacity in older adults un-
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independent prognostic value beyond traditional cardiovas-
cular assessment. However, interventions to correct periph-
eral abnormalities in patients with heart failure or sarcope-
nia in general are very limited. Controversy exists as to
whether pharmacologic interventions such as inhibition of
the renin-angiotensin-aldosterone system or beta-adrenergic
blockade have an impact on skeletal muscle derangements in
heart failure (24). Exercise interventions, primarily aerobic
exercise training, in patients with heart failure have resulted
in beneficial molecular and functional changes in skeletal
muscle, including improved oxidative function and higher
mitochondrial number and density (25), increased insulin-
like growth factor-1 expression (26), and reduced local
oxidative stress and inflammation (13). These molecular
changes correlate with increased exercise performance un-
derlined by longer exercise duration and higher peak VO2 as
well as improved endothelial function (10,25–27). No clear
data exist on the potential therapeutic role of anabolic
interventions such as growth hormone, testosterone, oxan-
drolone, megestrol acetate, the orexigenic peptide ghrelin,
high-dose fish oil, or amino acid supplements (28).
As most of these studies have been performed in patients
with reduced left ventricular systolic function, the specific
changes of skeletal muscle in patients with HFPEF are
unclear. Previous data have demonstrated that subclinical
electromyographic alterations indicative of myogenic myop-
athy as well as histologic alterations characterized by type 1
atrophy were common in patients with both dilated and
hypertrophic cardiomyopathy and were unrelated to the
degree of impairment of left ventricular function (29). The
current study extends these observations, suggesting that
skeletal muscle abnormalities contribute in large part to the
observed impairment in exercise performance and that
aerobic exercise training is beneficial. As most of these
investigations are based on the molecular analysis of skeletal
muscle biopsies, similar approaches are needed for the
analysis of skeletal muscle ultrastructure and metabolism in
the setting of HFPEF. Furthermore, noninvasive methods
such as nuclear magnetic resonance spectroscopy might
reveal abnormalities in metabolic intermediates, substrate
utilization, and phosphocreatine and glycogen storage pools.
The encouraging results of the Haykowsky et al. (3)
exercise intervention trial for HFPEF suggest that such
nonpharmacologic interventions may be a potential first-
line therapy for HFPEF. Ultimately, clinical trials aimed at
treating sarcopenia and pathologic muscle abnormalities
emerging from the heart failure syndrome hold great prom-
ise for ameliorating functional impairments and disability
associated with the epidemic of HFPEF.
In conclusion, the current study provides evidence for a
role of peripheral factors in patients with HFPEF and
implicates skeletal muscle metabolism and function in the
observed exercise intolerance in this subset of patients with
heart failure. As there is growing recognition of this patient
population and a lack of specific or symptomatic therapies,further studies on peripheral factors are highly warranted.
While the field might feel disadvantaged and left behind in
light of the overwhelming body of evidence accumulated on
patients with heart failure and reduced ventricular function,
that existing body of literature might stimulate focused and
detailed studies on peripheral skeletal muscle function in
HFPEF. The analysis of skeletal muscle oxidative metabo-
lism, fiber typing, mitochondrial function, and overall cap-
illarization on skeletal muscle biopsies and the nuclear
magnetic resonance spectroscopic analysis of muscle metab-
olism might be initial steps for the characterization of
skeletal muscle derangements in patients with HFPEF.
The syndrome of HFPEF is complex, and the underlying
cardiac dysfunction appears secondary given the complexity
of peripheral abnormalities that develop alongside the car-
diac phenotype. First steps have been taken but more needs
to be done, and certainly every step involves skeletal muscle
function and metabolism.
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